Exabis Library
Welcome to the e-CCO Library!
P432: Patient perspectives on biosimilars: a European Federation of Crohn’s and Colitis Associations survey
 2016
 ECCO '16 Amsterdam
 Friday, 22 February 2019, 9:49 AM
P432: Patient satisfaction and patient costs associated with telephone clinic appointments in Inflammatory Bowel Disease (IBD) following the pandemic
 2023
 ECCO’23 Copenhagen
 Friday, 14 July 2023, 11:05 AM
P432: Relationship between haemoglobin status and utility in patients with iron deficiency anaemia in inflammatory bowel disease: A post-hoc analysis of a phase 3 clinical trial
 2022
 ECCO'22
 Friday, 11 February 2022, 3:52 PM
P432: Therapeutic approaches for perianal fistula in paediatric and adolescent onset Crohn's disease – a multicentre cohort study
 2017
 ECCO '17 Barcelona
 Wednesday, 20 February 2019, 10:36 AM
P433 A real-world observational study assessing treatment persistence in ulcerative colitis patients receiving anti-TNF treatment (golimumab or adalimumab) 
 2020
ECCO'20 Vienna
 Thursday, 30 January 2020, 10:12 AM
P433: Aetiologies of iron deficiency-related anaemia in German patients with inflammatory bowel disease 
 2019
ECCO '19 Copenhagen
 Friday, 22 February 2019, 9:41 AM
P433: Canadian patient and caregiver perspectives on subsequent entry biologics / biosimilars for inflammatory bowel disease
 2016
 ECCO '16 Amsterdam
 Friday, 22 February 2019, 9:49 AM
P433: Efficacy of risankizumab by baseline clinical, biochemical, and endoscopic disease severity in moderately to severely active Crohn's disease
 2023
 ECCO’23 Copenhagen
 Friday, 14 July 2023, 11:05 AM
P433: Faecal calprotectin is correlated to endoscopic disease activity at Week 16 in IBD patients on vedolizumab therapy
 2018
 ECCO '18 Vienna
 Thursday, 21 February 2019, 9:14 AM
P433: Intravenous ustekinumab as maintenance treatment is effective in patients with partial or loss of response to optimized ustekinumab sc.
 2022
 ECCO'22
 Friday, 11 February 2022, 3:52 PM
P433: Postsurgical recurrence in Crohn's disease. Multicenter study in the region of Murcia, Spain of GEMEII group
 2017
 ECCO '17 Barcelona
 Wednesday, 20 February 2019, 10:36 AM
P433: Sex-based differences in response to tumor necrosis factor inhibitor induction therapy for ulcerative colitis: a pooled analysis of individual patient-level clinical trials data
 2021
 ECCO'21 Virtual
 Wednesday, 2 June 2021, 4:12 PM
P434 Effectiveness and safety of ustekinumab in ulcerative colitis: real-world evidence from Eneida Registry 
 2020
ECCO'20 Vienna
 Thursday, 30 January 2020, 10:12 AM
P434: Close rectal versus total mesorectal excision in patients with inflammatory bowel disease undergoing proctocolectomy or completion proctectomy
 2016
 ECCO '16 Amsterdam
 Friday, 22 February 2019, 9:49 AM
P434: Factors associated with medical and psycosocioeconomic changes in IBD during the COVID-19 pandemic and post-pandemic period
 2021
 ECCO'21 Virtual
 Wednesday, 2 June 2021, 4:12 PM
P434: Joint Inflammatory Bowel Disease–Obstetric clinics: outcomes in 95 pregnancies at a tertiary centre over a 3-year period
 2017
 ECCO '17 Barcelona
 Wednesday, 20 February 2019, 10:36 AM
P434: Remission induction in corticosteroid naive children and adolescents with active ulcerative colitis by adsorptive leucocytapheresis after failure of first-line medications: Results from routine clinical practice
 2018
 ECCO '18 Vienna
 Thursday, 21 February 2019, 9:14 AM
P434: Surgery management of Crohn's disease in children: our experience 
 2019
ECCO '19 Copenhagen
 Friday, 22 February 2019, 9:41 AM
P434: The PROPER study: interim analysis of a Pan-European real-world study of SB5 adalimumab biosimilar after transition from reference adalimumab in patients with Crohn’s disease
 2022
 ECCO'22
 Friday, 11 February 2022, 3:52 PM
P434: Upadacitinib improved fatigue and health-related quality of life in patients with moderately to severely active Crohn's disease: Results from induction and maintenance phase 3 trials
 2023
 ECCO’23 Copenhagen
 Friday, 14 July 2023, 11:05 AM